About OSTX Dividend Returns
OS Therapies Incorporated (OSTX) is a dividend-paying stock. When dividends are reinvested through a DRIP (Dividend Reinvestment Plan), they purchase additional shares, which then generate their own dividends—creating a compounding effect that can significantly boost long-term returns.
How We Calculate Total Return
Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.
Frequently Asked Questions
Q1What is the total return of OSTX over the past year?
OS Therapies Incorporated (OSTX) delivered a total return of -10.91% over the past year when dividends are reinvested. The price-only return was -10.91%, meaning dividends contributed an additional 0.00 percentage points to total returns.
Q2How much would $10,000 invested in OSTX be worth today?
A $10,000 investment in OS Therapies Incorporated one year ago would be worth $8,909 today with dividends reinvested (DRIP). Without reinvesting dividends, the same investment would be worth $8,909. Dividend reinvestment added $0 to the portfolio value.
Q3Does OSTX pay dividends?
Yes, OS Therapies Incorporated (OSTX) pays dividends. In the last year, OSTX paid approximately $1.50 per share in dividends (100.00% yield). Reinvesting these dividends through a DRIP can significantly boost long-term returns — over 20+ years, dividend compounding can account for 30–50% of total returns for dividend-paying stocks.
Q4Did OSTX beat the S&P 500?
No, OS Therapies Incorporated (OSTX) underperformed the S&P 500 by 26.36 percentage points over the past year. OSTX delivered a total return of -10.91%, compared to the S&P 500's 15.45%. This means a passive S&P 500 index fund outperformed OSTX by 26.36pp during this period.
Q5What is OSTX's worst drawdown?
OS Therapies Incorporated (OSTX) experienced a maximum drawdown of -53.60% over the past year, declining from its peak on 2025-08-27 to its trough on 2026-02-12. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.
Q6What is OSTX's long-term total return over 10, 20, or 30 years?
OS Therapies Incorporated (OSTX) has delivered strong long-term returns with dividends reinvested. Over 10 years, the total return is -41.4% (-5.2% CAGR) — $10,000 would have grown to $5,857. Over 20 years: -41.4% total return (-2.6% CAGR) — $10,000 → $5,857. Over 30 years: -41.4% total return (-1.8% CAGR) — $10,000 → $5,857. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.
Q7What was OSTX's best and worst year?
OS Therapies Incorporated's best calendar year was 2024 with a total return of 70.5%. Its worst year was 2025 with a total return of -66.5%. This range shows the volatility investors should expect — the difference between the best and worst year is 137.0 percentage points.
Find the Best Dividend Stocks
Screen for dividend stocks with the highest total returns (including DRIP).